Total | Pub1 | Pub2 | Prv1 (NGO) | Prv2 (GP) | Prv3 (Nurse) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
N=376 | n=76 | n=75 | n=75 | n=75 | n=75 | |||||||
Gender, n(%) | ||||||||||||
Male | 177 | (47%) | 17 | (22%) | 21 | (28%) | 29 | (39%) | 35 | (47%) | 12 | (16%) |
Female | 199 | (53%) | 59 | (78%) | 54 | (72%) | 46 | (61%) | 40 | (53%) | 63 | (84%) |
Age, n(%) | ||||||||||||
18-30 | 111 | (30%) | 30 | (39%) | 24 | (32%) | 22 | (29%) | 17 | (23%) | 18 | (24%) |
31-40 | 151 | (40%) | 29 | (38%) | 24 | (32%) | 35 | (47%) | 27 | (36%) | 36 | (48%) |
41-50 | 77 | (20%) | 13 | (17%) | 16 | (21%) | 14 | (19%) | 19 | (25%) | 15 | (20%) |
>50 | 37 | (10%) | 4 | (5%) | 11 | (15%) | 4 | (5%) | 12 | (16%) | 6 | (8%) |
Age, median (IQR) | 34 | (29.0-42.0) | 31.5 | (27.0-37.5) | 36 | (29.0-45.0) | 34 | (30.0-35.0) | 38 | (27.0-29.0) | 34 | (30.0-40.0) |
Baseline ART regimen, n (%) | ||||||||||||
Fixed dose combination (TDF-FTC-EFV) | 372 | (99%) | 75 | (99%) | 72 | (96%) | 75 | (100%) | 75 | (100%) | 75 | (100%) |
ABC-3TC-EFV | 4 | (1%) | 1 | (1%) | 3 | (4%) | 0 | (%) | 0 | (%) | 0 | (%) |
Baseline CD4 count, n (%) | ||||||||||||
<100 cells/mm3 | 42 | (11%) | 5 | (7%) | 14 | (19%) | 16 | (21%) | 7 | (9%) | - | |
101-200 cells/mm3 | 38 | (10%) | 5 | (7%) | 9 | (12%) | 10 | (13%) | 14 | (19%) | - | |
201-350 cells/mm3 | 73 | (19%) | 22 | (29%) | 14 | (19%) | 22 | (29%) | 15 | (20%) | - | |
>351 cells/mm3 | 124 | (33%) | 34 | (45%) | 29 | (39%) | 23 | (31%) | 38 | (51%) | - | |
Missing | 99 | (26%) | 10 | (13%) | 9 | (12%) | 4 | (5%) | 1 | (1%) | 75 | (100%) |
Baseline CD4 count, median (IQR) | 330 | (166-509) | 372 | (272-496) | 327 | (116-513) | 246 | (115-410) | 369 | (191-664) | - | |
ART naïve at enrolment, n (%) | 293 | (97%) | 73 | (96%) | 71 | (95%) | 74 | (99%) | 75 | (100%) | not reported | |
Mean days on ART at enrolment, if not ART naïve | 426 | 38 | 817 | 24 | - | not reported | ||||||
Mean number of comorbidities | 0.13 | 0.14 | 0.12 | 0.24 | not reported | 0.03 |